(Quartz) – Researchers at Imperial College London conducted a study on 200 patients who had one severely blocked artery to the heart, which starves the heart of oxygen and causes chest pain, especially when someone with the condition tries to exert themselves. For six weeks, the research team gave the participants statins and blood pressure medication, and then each patient underwent a routine procedure to insert a stent into the affected arteries. Except only about half of the patients actually got a stent.
(BBC) – Madagascar is facing the worst outbreak of plague in 50 years. There have been more than 1,800 cases and 127 deaths since the start of August, according to new figures. The island off the south-east coast of Africa is used to seeing about 400 cases of mostly bubonic plague in the same rural areas every year. But this year it has developed into the deadlier pneumonic version and spread to much more populated areas, including the capital.
(CNN) – Three new reports from the US Centers for Disease Control and Prevention bring both good and bad news about Americans’ health. Death rates for heart disease, cancer and HIV are all down in the United States in the year ending mid-2017 compared to the same period last year, according to one report published Friday by the CDC’s National Center for Health Statistics. Despite these “wins,” the overall mortality rate has increased from the same time last year, the report also indicated. This overall uptick includes the death rate for drug overdoses.
(Scientific American) – The speed and effectiveness of the psychedelic experience Casey describes has caught the attention of the Food and Drug Administration, despite the Drug Enforcement Administration’s 1985 classification of MDMA as a Schedule I substance—the murderer’s row of illicit drugs that include heroin and are deemed to have no medical value. This past August the FDA granted MDMA “breakthrough therapy” status in the treatment of PTSD, meaning it may provide a substantial improvement over existing therapies. The agency will work closely with MAPS—a privately funded research institute founded 31 years ago in Santa Cruz, California—to design and conduct phase III trials starting next spring. This marks the first time psychedelic-assisted psychotherapy will be monitored in phase III trials for possible prescription use.
(Milwaukee Journal Sentinel) – While sitting in séances and pursuing Marabou storks may seem like extreme measures, the data researchers gather in the field — everything from the size and frequency of bat litters, to the levels of virus in their blood serum — is being used to build mathematical tools that scientists hope will achieve a landmark in human health. They want to predict an infectious outbreak before it happens.
(STAT News) – Several West Virginia municipalities are suing The Joint Commission, claiming the Chicago-based health care accreditation group downplayed the dangers of prescription painkillers and helped fuel addictions. The Charleston Gazette-Mail reports that the cities of Charleston, Huntington and Kenova and the town of Ceredo filed the class-action lawsuit Thursday in Charleston.
(BBC) – The Red Cross has confirmed that more than $5m (£3.8m) of aid money was lost to fraud and corruption during the Ebola epidemic in West Africa. Auditors found overpriced supplies, salaries for non-existent aid workers and fake customs bills. The disease, which raged between 2014 and 2016, claimed at least 10,000 lives. It required a massive humanitarian operation costing hundreds of millions of dollars to bring it under control.
(ABC News) – A first attempt at gene therapy for a disease that leaves babies unable to move, swallow and, eventually, breathe has extended the tots’ lives, and some began to roll over, sit and stand on their own, researchers reported Wednesday. Only 15 babies with spinal muscular atrophy received the experimental gene therapy, but researchers in Ohio credited the preliminary and promising results to replacing the infants’ defective gene early — in the first few months of life, before the neuromuscular disease destroyed too many key nerve cells.
(MIT Technology Review) – For over a decade, scientists have been trying to reverse heart failure by delivering a new gene to the heart that makes it better at pumping blood and supplying the body with oxygen. A major clinical trial testing this gene therapy flopped in 2015. But as gene therapy has finally become a reality for other diseases after years in the making, there’s now renewed interest in trying it again for heart failure.
(GEN) – A new blood system isn’t created from scratch—just something close to it. A single type of stem cell, a new study demonstrates, can fully repopulate the bone marrow and give rise to all the cell lineages that constitute a complete blood system. This blood-forming stem cell is distinguished by three cell-surface markers—or rather the presence of two markers and the absence of a third. By heeding these markers, scientists may improve transplantation procedures, as well develop better gene therapy and gene-editing approaches.
(Quartz) – Last week, the US Food and Drug Administration issued a warning about advertisements for thermograms falsely claiming the technology could be as good or better than mammograms. In 1982, the FDA approved thermograms for breast-cancer screening—but only in conjunction with regular mammograms. Although thermography is not harmful in and of itself, there’s no scientific evidence that actually can detect breast cancer on its own. Since 2016, the FDA has issued two warnings to companies advertising preventative breast cancer screenings.
(Scientific American) – CRISPR–Cas9 (or CRISPR, for short) has given scientists a powerful way to make precise changes to DNA—in microbes, plants, mice, dogs and even in human cells. The technique may help researchers engineer drought-resistance crops, develop better drugs, cure genetic disorders, eradicate infectious diseases and much more. Ask any biologist, and they’ll likely tell you that CRISPR is revolutionary. It’s cheap and effective, and in many cases, it works much better than older methods for making genetic modifications. Biologists will also tell you that CRISPR is very easy to use. But what does “easy to use” mean?
(Wired) – So what can help? There is a category of jobs today that is critical to our society. Many of us will employ the services of these workers, but these positions are all-too-often held in low esteem with poor pay and minimal career advancement prospects. Some are designing so-called social robots to take these jobs. Yet, these are jobs we categorically do not want machines doing for us, though machines could potentially assist humans. I am speaking of caregiving.
(Reuters) – More than half of patients with a rare, rapidly progressing fatal genetic disorder experienced significant improvement after being treated with an Alnylam Pharmaceutical Inc drug that uses gene silencing technology, according to results of a late stage study released on Thursday. The drug, patisiran, was being tested against the life-shortening condition called hereditary ATTR (hATTR) amyloidosis with polyneuropathy, which affects an estimated 50,000 people worldwide. It is being developed in partnership with Sanofi.
(Medical Xpress) – Research presented today at the American Society for Reproductive Medicine (ASRM) by scientists from the University of Colorado and Duke University concludes that fresh donor eggs during in vitro fertilization (IVF) provide a higher chance of implantation when compared with donor eggs that have been cryopreserved. In addition, the study lends credence to the practice of transferring just one embryo during IVF to avoid complications that accompany multiple births, bucking the historically prevalent method of transferring two or more embryos to increase the odds of pregnancy.
(Wired) – There’s no lack of reports on the ethics of artificial intelligence. But most of them are lightweight—full of platitudes about “public-private partnerships” and bromides about putting people first. They don’t acknowledge the knotty nature of the social dilemmas AI creates, or how tough it will be to untangle them. The new report from the AI Now Institute isn’t like that. It takes an unblinking look at a tech industry racing to reshape society along AI lines without any guarantee of reliable and fair results.
(STAT News) – Our pediatric ethics committee reviewed numerous arguments and readings, including former U.S. Surgeon General C. Everett Koop’s 1977 case of conjoined twins with a shared heart. Our daily mission as physicians is to do no harm, ensure a child’s best interests, and honor a parent’s rights to make decisions for that child. How we could accomplish all three was something we dispassionately debated for endless hours over multiple weeks. Did we have a duty to act, or should we allow nature to take its course? Who decides what to do?
(Nature) – The first controlled, but controversial and small, clinical trial of giving young blood to people with dementia has reported that the procedure appears safe. It has also hinted that it may even produce modest improvements in the daily lives of people who have Alzheimer’s disease. Researchers who conducted the trial and others caution that the results are based on just 18 people and therefore are only a first step in exploring this type of treatment. “This is a really very small trial and the results should not be over-interpreted,” says Tony Wyss-Coray, a neurologist at Stanford University in California who led the study. The trial was conducted by his start-up company Alkahest, which is based in San Carlos, California.
(Reuters) – Researchers used electronic health records to hunt down the source of a potentially deadly hospital-acquired infection at the University of California, San Francisco. The culprit: a CT scanner in the hospital’s emergency department, according to a new report in JAMA Internal Medicine online October 23. The study was the first to use time and location stamps on electronic records to map patients throughout the hospital and track the course of an infectious agent.
(MIT Technology Review) – IVF clinics already test the DNA of embryos to spot rare diseases, like cystic fibrosis, caused by defects in a single gene. But these “preimplantation” tests are poised for a dramatic leap forward as it becomes possible to peer more deeply at an embryo’s genome and create broad statistical forecasts about the person it would become. The advance is occurring, say scientists, thanks to a growing flood of genetic data collected from large population studies.